| OCR Text |
Show LIST OF FIGURES Page Figures 2.1. METH-induced OAT complexes form in the striatum and not in the nucleus 24 accumbens 2.2. Intrastriatal 6-0HDA infusion causes OAT complex formation 2.3. 26 Eticlopride pretreatment attenuates OAT complex formation, the decreases in [3H1DA uptake, and the OAT monomer loss following METH28 treatment 2.4. SCH3390 pretreatment does not attenuate OAT complex formation, the decreases in [3H1DA uptake, nor the OAT monomer loss following METH30 treatment 2.5. OAT complex immunoreactivity negatively correlates and OAT monomer immunoreactivity positively correlates with [3H]DA uptake . 32 3.1. Time-course of METH-induced OAT complex formation and loss of OAT monomer immunoreactivity 44 3.2. Time-course of METH-induced alterations in VMAT2 and GFAP immunoreactivity 3.3. 46 Eticlopride pretreatment, but not SCH23390 pretreatment, attenuates METH-induced loss of VMAT2 as assessed 24 h after METHtreatment 3.4. 48 Eticlopride pretreatment attenuates METH-induced OAT complex formation and loss of OAT monomer immunoreactivity, as assessed 72 h following M ETH-treatm,ent 3.5. 5,0 Eticlopride pretreatment attenuates METH-induced loss of VMAT2 and increased GFAP immunoreactivity, as assessed 72 h following METHtreatment 52 |
